Meeting
2017 ASCO Annual Meeting
Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
Authors
Lei Xiao
Innovative Cellular Therapeutics Co., LTD., Shanghai, China
Lei Xiao , He Huang , Xiaojun Huang , Xiaoyan Ke , Yu Hu , Junmin Li , Qing Zhang , Yongxian Hu , Qian Jiang , Jiong Hu , Hongmei Jing , Xiaohong Zhang , Zhao Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT 02813837
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7028)
DOI
10.1200/JCO.2017.35.15_suppl.7028
Abstract #
7028
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu
Poster
2016 ASCO Annual Meeting
Determination of the effect of target site density on the efficacy of CD22 chimeric antigen receptor t-cell therapy to treat acute lymphoblastic leukemia.
First Author: Sang Nguyen
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples